Preclinical data demonstrate >90% reduction in human cytomegalovirus (HCMV) reactivation from latency, establishing proof-of-concept for SYN002 in human kidneys -- Data published in the American ...
Risk factors for ganciclovir-resistant CMV include D+/R- pairing, high CMV viral load, high level of immunosuppression (ie, use of antilymphocyte antibodies), and prolonged ganciclovir exposure. A ...
NEW ORLEANS — Maribavir, an antiviral once deemed promising for cytomegalovirus (CMV) infection but discarded after a negative phase 3 trial, has been shown to be effective in treatment-resistant and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results